You are right that big pharma has stayed away from depression. My hope is av101 works well as an adjunctive. Axsm went a long way on a positive phase 2 adjunctive study. The elevate trial is designed to minimize placebo effect, but no doubt depression is a hard nut to crack.
Time will tell. The anxiety drug does not need much funding to get through phase 3.
I think if this was a dead car bounce the bounce would have happened sooner.
News 
Market Data 
Discover 
